Blog dedicated to the continuous education in Gynecology and Endocrinology

 

Estrogen receptor (ER) is a major ..

DGYE-2010-0131.R1[507286]

Wincewicz, Andrzej; Baltaziak, Marek; Kanczuga-Koda, Luiza; Koda, Mariusz; Sulkowska, Urszula; Famulski, Waldemar

Abstract: Estrogen receptor (ER) is a major feature of endometrioid adenocarcinoma with significant impact on constitution of estrogen-responsiveness of this endometrial malignancy, in which STAT3 (signal transducer and activator of transcription) becomes hyperactivated. The aim of our study was to detect immunohistochemically and compare expressions of STAT3 with apoptosis regulators as Bak and Bcl-xL in regard to different pathological features and variably pronounced ER-alpha immunoprofile in 78 endometrioid adenocarcinomas. STAT3 was abundantly detected in nuclei of cancer cells in 54 cases thus pointing at its activation as an universal nuclear transcriptional factor. Bcl-xL and Bak were expressed in cytoplasm of malignant cells in 62 and 20 cancers respectively. STAT3 correlated both with Bcl-xL (p=0.001, r=0.365) and Bak (p<0.001, r=0.436) in all of endometrioid adenocarcinomas and variably in different subgroups of these tumors segregated in regard to grading, staging and patients’ age. Remarkably, only ER-alpha positive cancers retained these correlations in opposition to ER-alpha negative tumors with negativity defined as an immunoreactivity below 10%. CONCLUSIONS: ER-alpha receptor probably enhances interactions between STAT3 and Bcl-xL to be present in statistically significant manner. Presence of ER-alpha receptor seems to be crucial for relationships among Bcl-xL and STAT3 to occur in endometrioid adenocarcinomas.

Post to Twitter Post to Facebook

Ghrelin expression of endometrium hyperplasia and endometrioid carcinoma

DGYE-2010-0030.R1[488772]

Aydin, Suleyman (contact); Dagli, Ferda; Kocdor, Hilal; Gurates, Bilgin; Sahin, İbrahim; ozercan, Mehmet; Ozercan, İbrahim

In the present study we aimed to explore whether ghrelin expression had a role in distinguishing between benign, pre-malignant and malignant lesions of endometrium. Tissue ghrelin expressions of a total of 60 cases, who were diagnosed in the Pathology Department Laboratory of Fırat University Medical School, and of whom 10 were in the proliferation phase, 10 had simple hyperplasia without atypia, 10 had simple hyperplasia with atypia, 10 had complex hyperplasia without atypia, 10 had complex hyperplasia with atypia and 10 had endometrioid carcinoma cases, were examined using immunohistochemical method. more

Post to Twitter Post to Facebook

Antiproliferative effect of adiponectin on rat uterine leiomyoma ELT-3 cells

DGYE-2009-0307.R1[487605], Takeda, Takashi, Wakabayashi, Atsuko; Tsuiji, Kenji; Li, Bin; Sakata, Masahiro; Morishige, Ken-ichirou; Yaegashi, Nobuo; Kimura, Tadashi

Objective. Although fibroids greatly affect reproductive health, the pathophysiology and epidemiology are not well-known. Recently, we have reported the relationship between uterine leiomyoma and metabolic syndrome. Many studies have indicated that reductions in plasma adiponectin levels play major roles in the development of metabolic syndrome. more

Post to Twitter Post to Facebook

INSULINE RECEPTOR SUBSTRATE-2 GENE POLYMORPHISM: IS IT ASSOCIATED WITH ENDOMETRIAL CANCER?

Cayan Filiz DGYE-2009-0179 [ID 463733]

Objective: The G1057D polymorphism in the insulin receptor substrate-2 (IRS-2) gene has been reported to be associated with insulin resistance, obesity and type 2 diabetes. However little is known about its possible association with cancer. To investigate this association, we determined the distribution of its genotypes and frequency of alleles in endometrial cancer patients.
Methods: The study population consisted of 184 subjects: 44 patients with endometrial cancer and 140 controls without cancer. All the patients were primarily treated with surgical intervention. DNA was extracted from the leucocytes by high pure PCR template preparation kit. Genetic polymorphism of IRS-2 G1057D was detected by using polymerase chain reaction (PCR)-based restriction fragment-length polymorphism (RFLP).
Results: For IRS-2 G1057D polymorphism, there was a significant difference in genotype distribution and allele frequency between endometrial cancer patients and controls (p< 0.001). The risk for endometrial cancer was 4.87 times higher in the individuals with the IRS-2 DD genotype compared to the GG genotype (95% CI: 1.74-13.63 P=0.003). Also individuals with the IRS-2 D allele had a significantly higher risk of endometrium cancer compared with individuals with the IRS-2 G allele, with a relative risk of 2.23 (95% CI: 1.36-3.67, P=0,001) for cases compared with population controls.
Conclusion: These results suggest that IRS-2 G1057D polymorphism may be associated with endometrial cancer.

Post to Twitter Post to Facebook

THE RESULTS OF ADJUVANT RADIOTHERAPY IN ENDOMETRIAL CARCINOMA

Korcum Aylin

Abstract: Introduction: To examine the clinical characteristics and treatment outcomes in patients with endometrial cancer receiving adjuvant radiotherapy. Methods: A total of 157 patients who received postoperative radiotherapy between 1999 and 2008 were evaluated retrospectively. The mean age was 59 years (34-82). All patients received radiotherapy following surgery. Stage distribution was as follows: 92 patients (59%) stage I, 21 patients (13%) stage II, and 44 patients (28%) stage III. Results: Overall survival rate was 95% at 2 years and 84% at 5 years. By the end of follow up, 135 patients (86%) were disease-free, and 4 (2%) were alive with disease. Univariate and multivariate analyses identified stage, grade, and serosal involvement as significant predictors for overall survival. Conclusion: The results of our study suggests that early stage, low-grade endometrial cancer with no serosal involvement is associated with a better survival and adjuvant radiotherapy is a well tolerated and effective therapeutic option.

Post to Twitter Post to Facebook

© International Society of Gynecological Endocrinology - Privacy Policy